Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
02:00pm, Wednesday, 28'th Aug 2024
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
2 Must-Buy Medical Stocks With Strong Momentum
09:06am, Wednesday, 28'th Aug 2024
Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
09:15am, Tuesday, 27'th Aug 2024
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances ac
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
12:20pm, Monday, 26'th Aug 2024
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
10:34pm, Tuesday, 20'th Aug 2024
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 20
Illumina Looks Bullish (Technical Analysis)
12:25pm, Sunday, 18'th Aug 2024
ILMN has shown bullish signs with price action improving, above 30-week EMA, and potential for trend change. Volume analysis indicates institutional buying, momentum is short-term bullish, and long-te
Illumina, Inc. (ILMN) Illumina 2024 Strategy Update Special Call
07:49pm, Tuesday, 13'th Aug 2024
Illumina, Inc. (NASDAQ:ILMN ) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ET Company Participants Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur Dhin
Illumina, CRISPR-pioneer Broad Institute to work on new gene sequencing kits
01:10pm, Tuesday, 13'th Aug 2024
Illumina said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene sequencing using a novel method based on the Nobel Prize-winning CRISPR technolo
Illumina announces strategy to accelerate value creation
11:00am, Tuesday, 13'th Aug 2024
-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications us
Understanding Illumina (ILMN) Reliance on International Revenue
10:21am, Monday, 12'th Aug 2024
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View
09:46am, Monday, 12'th Aug 2024
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Illumina, Inc. (ILMN) Q2 2024 Earnings Call Transcript
09:32pm, Tuesday, 06'th Aug 2024
Illumina, Inc. (NASDAQ:ILMN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Offi
Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics
08:00pm, Tuesday, 06'th Aug 2024
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Illumina (ILMN) Q2 Earnings and Revenues Top Estimates
07:27pm, Tuesday, 06'th Aug 2024
Illumina (ILMN) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.32 per share a year ago.
Illumina expects full-year sales from core segment to decline on biotech funding crunch
06:54pm, Tuesday, 06'th Aug 2024
Gene sequencing machine maker Illumina on Tuesday forecast 2024 sales from its core segment to decline, a sign that subdued demand for its instruments used in genetic tests could extend further into t
